Editor LSA

Volume Actives: Brocade Communications Systems, Inc. (NASDAQ:BRCD), GenVec Inc , Catalyst Pharmaceutical Partners, Inc. , Extreme Networks, Inc

 

Lewes, DE -- (SBWIRE) -- 09/25/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Brocade Communications Systems, Inc. (NASDAQ:BRCD), GenVec Inc (NASDAQ:GNVC), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Extreme Networks, Inc(NASDAQ:EXTR).

Brocade Communications Systems, Inc. (NASDAQ:BRCD), decreased -0.30% and closed at $8.18 on a traded volume of4.70million shares, in comparison to 7.32 million shares of average trading volume. So far this year, the stock is up over 53.47%.

The company has a total market capitalization of $3.66million and its total outstanding shares are 447.34million.

Will BRCD Get Buyers Even After The Recent Rally? Find Out Here

Pan American Silver Corp. engages in the exploration, development, and operation of silver producing properties and assets. It produces and sells silver, gold, copper, lead, and zinc.

GenVec Inc (NASDAQ:GNVC), soared35.14% and closed at $1.50 on a traded volume of 4.33 million shares, whereas its average trading volume is 671,812 shares. In the last three months, the stock is up328.45%. The Intra-day range for the stock is $1.13 and $1.69.

Will GNVC Continue To Move Higher? Find Out Here

GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), jumped up7.32 % and closed at $3.08. So far in three months, the stock is up 246.11%. The 52-week range for the stock is $0.37 and $3.24 and during the previous trading session it marked$3.24 as its highest price. The stock initially exchanged hands with a price of $2.96 and the overall traded volume that day was 4.28 million shares.

Will CPRX Continue To Move Higher? Find Out Here

Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.

Extreme Networks, Inc(NASDAQ:EXTR), after opening its shares at the price of $5.11, dropped -1.00% to close the day at $5.04. The stock ended on a traded volume of 4.18 million shares, in comparison to 1.47 million shares of average trading volume. The 52-week range for the stock is $2.99 and $5.23 and during the previous trading session the stock scored the highest price of $5.23. It started the day at $5.11.

Will EXTR Get Buyers Even After The Recent Rally? Find Out Here

Extreme Networks, Inc., together with its subsidiaries, provides network infrastructure equipment and services for enterprises, data centers, and service providers.

About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/